White fat browning may be a metabolic ally or a cancer risk, review finds
image: Graphical overview of white adipose tissue browning, showing how white adipocytes can acquire thermogenic beige/brown-like features through molecular and environmental cues, with context-dependent effects on metabolic diseases, tumors and cancer-associated cachexia.
Credit: Yingjiao Wang, Diyuan Zhang, Yuqin Zhou, Ling Qian et al.
Chongqing, China - A new review published in Med Research examines a deceptively simple question with major implications for metabolic disease and cancer: when should white fat be encouraged to burn energy, and when should that same process be restrained?
White adipose tissue (WAT) is commonly known as the body's energy-storage depot. Under certain stimuli, however, white adipocytes can acquire features of beige or brown fat cells, including higher mitochondrial activity, increased fatty acid oxidation and elevated expression of uncoupling protein 1 (UCP1). This process, known as WAT browning, increases thermogenesis and energy expenditure.
The review, "White Adipose Tissue Browning and Cross Talk With Metabolic Diseases and Tumors: From Molecular Mechanisms to Clinical Translation," was led by researchers from the Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University, and the Key Laboratory of Chongqing Health Commission for Minimally Invasive and Precise Diagnosis and Treatment of Breast Cancer. The authors summarize molecular and cellular pathways that shape WAT browning, including PRDM16, PPARgamma, PGC-1alpha, UCP1, hormone and sympathetic signaling, noncoding RNAs, epigenetic regulation, fatty acid metabolites, gut microbiota and immune cells.
The review highlights that browning is not controlled by a single switch. It can be induced by external and internal stimuli, including cold exposure, local hyperthermia, electroacupuncture, exercise, diet, natural products and gut microbiota modulation. Many of these pathways converge on mitochondrial biogenesis, thermogenic gene expression, lipid oxidation and immune-microenvironment remodeling.
In obesity and metabolic syndrome, moderate WAT browning may be beneficial because it can increase energy use, reduce lipid accumulation, improve insulin sensitivity and support healthier cardiometabolic function. These features have made browning an attractive concept for treating obesity, insulin resistance and related metabolic disorders.
The same biology can be risky in cancer. In some settings, browning may compete with tumors for nutrients or reshape the tumor microenvironment in ways that suppress growth. In other settings, especially advanced tumors and cancer-associated cachexia, persistent activation of thermogenesis may worsen energy depletion, fat loss, skeletal muscle wasting and poor nutritional status. The authors therefore frame WAT browning as a "double-edged sword" rather than a universally helpful "fat-burning" program.
The review also assesses translational strategies, including GLP-1 receptor agonists and local photothermal nanomaterials. GLP-1 receptor agonists are already important in metabolic disease management, and some studies suggest links with thermogenic pathways and adipose immune regulation. Photothermal nanomaterials may allow more localized activation of subcutaneous fat browning, potentially reducing systemic exposure. However, the authors emphasize that tissue targeting, dosing intensity, delivery depth, long-term safety, species differences, regulatory requirements and ethical considerations remain major hurdles.
The central message is precision. Future interventions should ask not only whether browning can be activated, but when, where, for whom and how strongly. In energy-surplus states such as obesity, carefully targeted subcutaneous fat browning may be useful. In energy-depleted states such as cancer-associated cachexia, suppressing abnormal browning and preserving body composition may be more appropriate.
By integrating molecular mechanisms with disease context, the review provides a framework for safer clinical translation of adipose tissue plasticity research. The authors call for stratified clinical studies, standardized endpoints and monitoring systems that evaluate body weight, body composition, metabolism, inflammation, tumor outcomes and quality of life together.
(Expert Contact: Xiaowei Qi, Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University; Email: qxw9908@foxmail.com. Yi Zhang, Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University; Email: yzhang@tmmu.edu.cn.)
(Custom Tweet: White fat browning may help combat obesity but can worsen tumor-related wasting. A Med Research review maps how to target this metabolic switch safely.)